|
KLS is a manufacturer of outdoor fitness equipment and a producer of pharmaceutical active ingredients and specialty chemicals. In its Chemical segment, the company manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates for generic and original drugs, primarily serving the Japanese market. It also produces antimicrobial agents, including pyridinone-based products under the brand name CleanBio, for use in personal care and marine antifouling coatings. Key customers in this segment include multinational corporations such as Unilever, Procter & Gamble, and Henkel, as well as Japanese pharmaceutical firms. In its Bio segment, KLS engages in the research and development of cell and gene therapies, with a pipeline including TG-C for osteoarthritis, KLS-2031 for neuropathic pain, and KLS-3021, a oncolytic virus. The company provides contract development and manufacturing organization (CDMO) services and has entered into technology transfer agreements for its bio-products. In its Sports Equipment segment, KLS produces and sells outdoor fitness facilities, including high-end, multi-function, and modern stainless steel series, as well as walking mats, primarily for the domestic Korean market. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Specialty Chemicals | Homepage kls.kr |
| Sector Basic Materials | IR page — | |
|
Tags
active pharmaceutical ingredients, antimicrobial agents, cell and gene therapy, cdmo services, outdoor fitness equipment, marine coatings, personal care ingredients, phosphoramidite, CleanBio, TG-C, KLS-2031, KLS-3021, Inbosakeju, BM102, Juniper Biologics, Pine Pharmaceuticals, Kolon Life Science
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| Market cap (USD) | — |
| P/E | — |
| PEG | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 6.8% |
| ROI | 4.3% |
| ROIC | 2.9% |
| Profit margin | 11.9% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 127.0% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 36.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 208.982B | 161.387B | 124.639B | 161.584B | 132.267B | 129.413B | 148.541B | 132.68B | 118.102B | 158.284B | 121.175B | 130.633B | 139.611B |
| Net profit | 24.96B | -93.086B | -30.726B | 2.133B | -1.375B | -43.195B | -92.323B | -50.69B | -1.404B | 12.665B | 800.139M | 5.855B | 17.228B |
| Free cash flow | -28.055B | -22.279B | -35.009B | -27.159B | -20.6B | -10.05B | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 21.5B | 21.7B | 24.5B | 29.5B | 34.9B | 20.3B | 29.8B | 26.1B | 38.5B | 37.7B |
| ↳ YoY growth | +24.3% | +1.0% | +13.1% | +20.1% | +18.6% | -41.9% | +46.6% | -12.4% | +47.8% | -2.1% |
| ↳ 5y CAGR | +2.0% | +10.3% | +15.1% | -1.1% | +6.5% | +1.2% | +5.5% | +1.5% | ||
| Borrowings, current (KRW) | 28.9B | 38.6B | 40.5B | 60.3B | 67.1B | 59.1B | 73.5B | 97.3B | 116B | 97.2B |
| Borrowings, non-current (KRW) | 18.6B | 10.4B | 24.6B | 18.1B | 9.33B | — | — | 9.98B | 8.7B | 4.99B |
| Bonds payable (KRW) | — | — | — | — | — | — | 0.00 | 0.00 | 9.99B | 7.82B |
| Lease liabilities (KRW) | — | 0.00 | 0.00 | 376M | 611M | 527M | 455M | 620M | 2.02B | 1.59B |
| Cash and deposits (KRW) | 138B | 55.8B | 32.7B | 5.91B | 15B | 27.8B | 6.37B | 7.56B | 12.5B | 10.6B |
| Intangible assets (KRW) | 11.8B | 17.1B | 8.43B | 900M | 722M | 1.72B | 343M | 333M | 599M | 1.03B |
| Right-of-use assets (KRW) | — | 0.00 | 0.00 | 361M | 594M | 513M | 459M | 639M | 2.08B | 1.59B |
| Net debt (borrowings + leases - cash) (KRW) | -90.2B | -6.78B | 32.4B | 72.8B | 62B | 31.8B | 67.5B | 90.3B | 105B | 93.1B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 28.1B | -8.29B | -13.6B | -20.2B | -7.31B | -16.2B | -20.9B | -24.9B | -14.1B | 10.2B |
| Purchases of property, plant and equipment (KRW) | — | — | -42.4B | -30.8B | -2.74B | -4.41B | -6.31B | -10.1B | -8.19B | -38.3B |
| Purchases of intangible assets (KRW) | -1.62B | -605M | -2.83B | -5.78M | 0.00 | -43M | -2.2M | -93.3M | -532M | -124M |
| Change in receivables (cash effect) (KRW) | -3.85B | — | — | — | — | 3.25B | -10.5B | 4.21B | — | — |
| Change in inventories (cash effect) (KRW) | 656M | -11.6B | -2.92B | -2.72B | -3.55B | -3.81B | -23.8B | -2.13B | — | — |
| Change in payables (cash effect) (KRW) | 9.35B | — | — | — | — | 2.17B | 4.53B | -5.57B | — | — |
| Dividends paid (cash effect) (KRW) | -668M | -1.52B | 0.00 | 0.00 | — | — | — | — | — | — |
| Share buybacks (cash effect) (KRW) | 0.00 | 0.00 | -462M | 0.00 | 0.00 | — | — | — | — | — |
| Interest paid (cash effect) (KRW) | -1.91B | -1.51B | -1.64B | -2.4B | -2.04B | -2.46B | -2.99B | -5.12B | -7.44B | -6.63B |
| Income taxes paid (cash effect) (KRW) | -2.86B | -377M | 92.6M | 124M | 135,342 | 32.9M | -818,530 | -113M | 6.78M | -268M |
| Operating cash flow before change in receivables (KRW) | 32B | — | — | — | — | -19.4B | -10.4B | -29.1B | — | — |
| Free cash flow (OCF - PPE - intangibles) (KRW) | — | — | -58.9B | -51B | -10.1B | -20.6B | -27.2B | -35.1B | -22.8B | -28.2B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 11B | 287B | -98.8B | -345B | -43.1B | -108M | 67.9B | -30.1B | 2.77B | 390B |
| Comprehensive income to owners (KRW) | — | — | — | — | — | — | 67.9B | -30.1B | 2.77B | 390B |
| Provision for credit losses (KRW) | — | 0.00 | 0.00 | 260M | 116M | 0.00 | 0.00 | 78M | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | — | 0.0% | 0.0% | 1.0% | 0.4% | 0.0% | 0.0% | 0.3% | — | — |
| Reported | Mar 31, 2017 | Mar 30, 2020 | Mar 17, 2021 | Mar 17, 2021 | Mar 17, 2021 | Mar 21, 2024 | Mar 18, 2025 | Mar 18, 2026 | May 15, 2025 | Mar 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpNews
Disclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding KLS
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.00% | 556 | $ 4,815.34 | Nov 16, 2026 |